(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Hostages as leverage: Iran's secret demand aimed at crippling Israel's agriculture - 210 Distinct Kinds of Chinese Neighborhood Specialty Hot Pot
- 3Parents who delay baby's first vaccines also likely to skip measles shots
- 4Exposure to neighborhood violence leads some Denver teens to use tobacco and alcohol earlier, new study shows
- 5Antimatter took to the road for the very first time. Here’s why it matters
- What to expect from the planets in 2026 — key dates and sky events
- Gaza Strip sees flooding after heavy rainfall
- Energy security rifts widen in Europe
- Bitcoin momentum builds in Abu Dhabi as global interest surges
- 5 Eating routine Well disposed Snacks to Keep You Fulfilled
- 'Every day I planned an escape': Ariel Cunio shares details of Hamas captivity
- Travels to Dream Objections in Europe
- RFK Jr.’s vaccine advisers plan biggest change yet to childhood schedule
- What's The Friendliest City In The United Kingdom?
